FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
Fortress Biotech, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.87+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $59.45M
- P/E (TTM)
- –
- Dividend yield
- –
Fortress Biotech, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | $61.86M | $56.13M | $79.18M | – | – | – | – | – | – | – | 97.8% | +10.2% |
| Avenue | $1.40M | – | – | – | – | – | – | – | – | – | 2.2% | – |
| Pharmaceutical and Biotechnology Product Development | – | – | $5.33M | $2.07M | $5.66M | $1.07M | $1.71M | $3.51M | $1.73M | $2.57M | – | – |
| Dermatology Products Sales | – | – | $79.18M | $73.67M | $63.13M | $44.53M | $34.92M | $23.38M | $15.52M | $3.59M | – | – |
| Financial Service Activities [Member] | – | – | – | – | – | – | – | – | $170.34M | $10.32M | – | – |
| Consolidated [Member] | – | – | – | – | – | – | – | $26.88M | $17.25M | – | – | – |
| Checkpoint Merger | – | $41.00K | $103.00K | – | – | – | – | – | – | – | – | – |
| Fortress | – | $1.50M | $5.23M | – | – | – | – | – | – | – | – | – |
| TGTX [Member] | – | – | – | – | – | – | – | $3.51M | $1.73M | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mustang | -$2.43M | -$16.25M | -$49.26M | – | – | – | – | – | – | – | -85.0% |
| Avenue | -$3.08M | -$11.28M | -$14.54M | – | – | – | – | – | – | – | -72.7% |
| Journey | -$8.17M | -$13.68M | -$2.07M | – | – | – | – | – | – | – | -40.3% |
| Fortress | -$18.50M | -$13.00M | -$24.32M | – | – | – | – | – | – | – | +42.3% |
| Checkpoint Merger | -$38.04M | -$56.17M | -$52.15M | – | – | – | – | – | – | – | -32.3% |
| Pharmaceutical and Biotechnology Product Development | – | – | – | – | – | – | -$106.37M | -$134.63M | -$97.83M | -$59.32M | – |
| Dermatology Products Sales | – | – | – | – | – | – | $4.71M | $3.83M | $312.00K | -$4.45M | – |
| Financial Service Activities [Member] | – | – | – | – | – | – | – | – | -$11.41M | -$1.94M | – |
| Consolidated [Member] | – | – | – | – | – | – | – | -$130.80M | -$97.51M | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qbrexza | $25.01M | $25.11M | $25.41M | $26.72M | $17.06M | $0 | – | – | – | – | 39.5% | -0.4% |
| Emrosi | $14.75M | $0 | – | – | – | – | – | – | – | – | 23.3% | – |
| Accutane | $12.88M | $19.41M | $20.17M | $18.37M | $10.05M | $0 | – | – | – | – | 20.4% | -33.6% |
| Foam franchise products (Amzeeq & Zilxi) | $5.86M | $6.65M | – | – | – | – | – | – | – | – | 9.3% | -11.9% |
| Other / legacy product revenue | $2.74M | $3.96M | $5.92M | – | – | – | – | – | – | – | 4.3% | -30.9% |
| Royalty revenue | $0 | – | – | – | – | – | $100.00K | $400.00K | $1.00M | – | 0.0% | – |
| Other Branded Revenue | – | – | – | – | $37.00K | -$148.00K | $6.85M | $2.15M | $1.77M | – | – | – |
| Targadox | – | – | $3.20M | $7.97M | $22.38M | $30.71M | $28.07M | $21.23M | $13.75M | – | – | – |
| Return Reserve [Member] | – | – | – | – | – | – | $2.90M | $2.40M | $1.20M | – | – | – |
| License and Service [Member] | – | – | – | – | – | – | $1.70M | $3.50M | – | – | – | – |
| Ximino | – | – | $287.00K | $4.96M | $8.25M | $9.52M | $3.60M | – | – | – | – | – |
| Exelderm | – | – | $2.40M | $3.46M | $5.36M | $4.45M | – | – | – | – | – | – |
| Zilxi | – | $1.64M | $1.96M | $2.27M | $0 | – | – | – | – | – | – | – |
| Amzeeq | – | $5.01M | $6.20M | $7.24M | $0 | – | – | – | – | – | – | – |
| Luxamend | – | – | $35.00K | $0 | – | – | – | – | – | – | – | – |
| Collaboration revenue | – | $1.50M | $5.23M | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Fortress Biotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.